University of California

Sugen Incorporated

Fairooz F Kabbinavar

Peng Cho Tang

Axel Ullrich

Istvan Szekely

Aviv Gazit

Dennis J Slamon

Klaus Peter Hirth

Laura Kay Shawver

Alex Levitzki

Elaina Mann

Donna Pruess Schwartz

Reiner Lammers

Janis Haimichael

Tamas Bajor

Gyorgi Keri

The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

Treatment of platelet derived growth factor related disorders such as

Growing community of inventors

Woodland Hills, CA, United States of America

Fairooz F Kabbinavar